Avastin as effective as Eylea for treating central retinal vein occlusion

May 9, 2017

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI), part of the National Institutes of Health. After six monthly injections, treatment with either drug improved visual acuity on average from 20/100 to 20/40.

"This head-to-head comparison of two widely used drugs for of macular due to central shows that both are effective in improving vision," said Ingrid U. Scott, M.D., M.P.H., professor of ophthalmology and public health sciences at Penn State University, Hershey, Pennsylvania, and chair of the study. "The bottom line is that in patients with CRVO-associated macular edema, Avastin was as effective as Eylea in terms of after six months of treatment."

Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy and is estimated to affect more than 16 million adults worldwide. Associated with conditions such as hypertension and diabetes mellitus, CRVO occurs when the central vein that carries blood away from the retina, the light-sensitive tissue in the back of the eye, becomes blocked. When blood flow is disrupted, adequate levels of oxygen fail to reach the retina, triggering the release of vascular endothelial growth factor (VEGF). VEGF increases the permeability of blood vessels, leading to swelling in the central part of the retina—a condition known as macular edema, the leading cause of vision loss from CRVO.

Eylea is an anti-VEGF drug approved by the Food and Drug Administration for treatment of CRVO-associated macular edema. Avastin is a less expensive anti-VEGF drug ($60 per dose, versus $1850 per dose for Eylea). Avastin is an FDA approved biologic for treating cancer, but is frequently used off-label to treat conditions of the eye, including CRVO. Anti-VEGF drugs make the injured blood vessels less leaky, thereby decreasing macular edema. The Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) evaluated the comparative safety and efficacy of the two drugs.

The SCORE2 researchers recruited 362 patients with CRVO-associated macular edema from 66 clinical sites throughout the United States and randomly assigned them to receive either Eylea (2.0 milligrams) or Avastin (1.25 milligrams) by eye injection every four weeks for six months. At six months, the researchers assessed visual acuity, retinal thickness, and side effects of the medications.

SCORE2 results, published today in the Journal of the American Medical Association, show that average visual acuity in both groups improved about four lines on an eye chart, from about 20/100 visual acuity to 20/40 visual acuity.

"This is a remarkable improvement in vision," said Frederick Ferris, M.D., director of the Division of Epidemiology and Clinical Applications at NEI. "On average, it more than doubles the ability to resolve fine detail, and for some patients it restores their ability to drive."

Using optical coherence tomography (OCT) to image retinal thickness, the researchers also found that macular edema decreased significantly in both groups. Complete resolution of macular edema occurred in a higher percentage of eyes in the Eylea group (54 percent) than in the Avastin group (29 percent). However, the lower proportion of eyes that had resolution of macular edema in the Avastin group did not translate into poorer visual acuity outcomes in that group at 6 months, said Scott. SCORE2 researchers will continue the study to investigate the cumulative effect of injections over a longer time frame and to evaluate the effects of residual edema.

"There is little information about the long-term treatment needs of patients with CRVO-associated macular edema," explained Scott. "The clinical trials that were conducted for the approval of Eylea for CRVO-associated were relatively short-term, and there have been reports of patients with CRVO requiring treatment several years out. There is important additional information that can be gained with longer follow-up of SCORE2 participants."

At six months, the rates of adverse events, such as elevated intraocular pressure, were low and similar in both groups.

"SCORE2 results provide invaluable data to guide clinicians and their patients toward informed decisions about CRVO treatment," said Sangeeta Bhargava, Ph.D., program director at NEI.

Explore further: Eylea outperforms other drugs for diabetic macular edema with moderate vision loss

Related Stories

Eylea outperforms other drugs for diabetic macular edema with moderate vision loss

February 18, 2015
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when ...

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss

February 28, 2016
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), ...

Central retinal vein occlusion ID'd after phendimetrazine use

February 8, 2016
(HealthDay)—A case of central retinal vein occlusion (CRVO) two days after phendimetrazine use has been documented and published online Feb. 4 in JAMA Ophthalmology.

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma

March 16, 2017
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

Aflibercept rescues vision after laser for diabetic macular edema

December 29, 2016
(HealthDay)—For eyes experiencing substantial visual loss after macular laser photocoagulation treatment for diabetic macular edema (DME), intravitreal aflibercept improves visual and anatomic outcomes, according to a study ...

Recommended for you

Study indicates proof of concept for using a surrogate liquid biopsy to provide genetic profile of retinoblastoma tumors

October 12, 2017
Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. Unlike most cancers that are diagnosed ...

Farsighted children struggle with attention, study finds

October 10, 2017
Farsighted preschoolers and kindergartners have a harder time paying attention and that could put them at risk of slipping behind in school, a new study suggests.

New drug reduces rate of progression of incurable eye disease

October 4, 2017
An international study including researchers from the Centre for Eye Research Australia (CERA) has found a way to slow the progression of dry age-related macular degeneration (AMD) - one of the most common causes of vision ...

Gene therapy shows promise for reversing blindness

October 2, 2017
Most causes of untreatable blindness occur due to loss of the millions of light sensitive photoreceptor cells that line the retina, similar to the pixels in a digital camera.

Discovery provides glimmer of hope to prevent blindness

September 27, 2017
Macquarie University researchers have discovered that a naturally occurring protein in the body protects the eye from the common eye disease glaucoma, and which is particularly sensitive to oxidation through environmental ...

Coming soon: Glaucoma self-care, from home?

September 23, 2017
(HealthDay)—For many glaucoma patients, repeat trips to a doctor's office to check on their eyes can be a real pain.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.